Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMallah, Narmeen
dc.contributor.authorZapata‑Cachafeiro, Maruxa
dc.contributor.authorAguirre, Carmelo
dc.contributor.authorIbarra‑García, Eguzkiñe
dc.contributor.authorPalacios-Zabalza, Itziar
dc.contributor.authorMacías García, Fernando
dc.contributor.authorVidal Guitart, Xavier
dc.contributor.authorVendrell Bosch, Lourdes
dc.contributor.authorIbáñez, Luisa
dc.date.accessioned2023-01-11T12:58:15Z
dc.date.available2023-01-11T12:58:15Z
dc.date.issued2022
dc.identifier.citationMallah N, Zapata-Cachafeiro M, Aguirre C, Ibarra-García E, Palacios-Zabalza I, Macías-García F, et al. Synergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study. Ann Med. 2022;54(1):379–92.
dc.identifier.issn1365-2060
dc.identifier.urihttps://hdl.handle.net/11351/8802
dc.descriptionGenetic variation; Non-steroidal anti-inflammatory drugs; Upper gastrointestinal haemorrhage
dc.description.abstractBackground Interindividual genetic variations contribute to differences in patients’ response to drugs as well as to the development of certain disorders. Patients who use non-steroidal anti-inflammatory drugs (NSAIDs) may develop serious gastrointestinal disorders, mainly upper gastrointestinal haemorrhage (UGIH). Studies about the interaction between NSAIDs and genetic variations on the risk of UGIH are scarce. Therefore, we investigated the effect of 16 single nucleotide polymorphisms (SNPs) involved in drug metabolism on the risk of NSAIDs-induced UGIH. Materials and methods We conducted a multicenter case-control study of 326 cases and 748 controls. Participants were sub-grouped into four categories according to NSAID exposure and genetic profile. We estimated odds ratios (ORs) and their 95% confidence intervals (CI) using generalized linear mixed models for dependent binomial variables and then calculated the measures of interaction, synergism index (S), and relative excess risk due to interaction (RERI). We undertook stratified analyses by the type of NSAID (aspirin, non-aspirin). Results We observed an excess risk of UGIH due to an interaction between any NSAID, non-aspirin NSAIDs or aspirin and carrying certain SNPs. The greatest excess risk was observed for carriers of: rs2180314:C>G [any NSAID: S = 3.30 (95%CI: 1.24–8.80), RERI = 4.39 (95%CI: 0.70–8.07); non-aspirin NSAIDs: S = 3.42 (95%CI: 1.12–10.47), RERI = 3.97 (95%CI: 0.44–7.50)], and rs4809957:A>G [any NSAID: S = 2.11 (95%CI: 0.90–4.97), RERI = 3.46 (95%CI: −0.40–7.31)]. Aspirin use by carriers of rs6664:C>T is also associated with increased risk of UGIH [ORaspirin(+),wild-type: 2.22 (95%CI: 0.69–7.17) vs. ORaspirin(+),genetic-variation: 7.72 (95%CI: 2.75–21.68)], yet larger sample size is needed to confirm this observation. Conclusions The joint effect of the SNPs s2180314:C>G and rs4809957:A>G and NSAIDs are more than three times higher than the sum of their individual effects. Personalized prescriptions based on genotyping would permit a better weighing of risks and benefits from NSAID consumption.
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesAnnals of Medicine;54(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectHemorràgia gastrointestinal
dc.subjectAntiinflamatoris no esteroïdals - Efectes secundaris
dc.subject.meshGastrointestinal Hemorrhage
dc.subject.mesh/chemically induced
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal
dc.subject.mesh/adverse effects
dc.titleSynergism interaction between genetic polymorphisms in drug metabolizing enzymes and NSAIDs on upper gastrointestinal haemorrhage: a multicenter case-control study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/07853890.2021.2016940
dc.subject.decshemorragia gastrointestinal
dc.subject.decs/inducido químicamente
dc.subject.decsantiinflamatorios no esteroideos
dc.subject.decs/efectos adversos
dc.relation.publishversionhttps://doi.org/10.1080/07853890.2021.2016940
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Mallah N] Department of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain. WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain. Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBER-ES), Carlos III Health Institute, Madrid, Spain. [Zapata-Cachafeiro M] Department of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain. Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Carlos III Health Institute, Madrid, Spain. [Aguirre C] Pharmacotherapy Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. Basque Country Pharmacovigilance Unit, University Hospital of Galdakao-Usansolo, Osakidetza, Spain. Pharmacology Department, Medicine and Nursing Faculty, University of the Basque Country, Barakaldo, Spain. [Ibarra-García E] Department of Preventive Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain. Pharmacotherapy Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. Osakidetza Basque Health Service, Pharmacy Department, Urduliz Hospital, Urduliz, Spain. [Palacios-Zabalza I] Pharmacotherapy Group, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. Basque Country Pharmacovigilance Unit, University Hospital of Galdakao-Usansolo, Osakidetza, Spain. [Macías-García F] Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. [Ibáñez L, Vidal X, Vendrell L] Catalonian Institute of Pharmacology, Barcelona, Spain. Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35114859
dc.identifier.wos000751793600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record